ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.
- ResMed continues to innovate in healthcare, potentially enhancing its market position.
- The upcoming earnings call may provide insights into future growth and operational strategies.
- The lack of specific financial data in the PR may leave investors uncertain about performance metrics.
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
Earnings webcast details:
| • | Location: | http://investor.resmed.com | |
| • | Date: | Thursday, October 27, 2022 | |
| • | Time: | 1:30 p.m. PDT / 4:30 p.m. EDT | |
| • | International: | London, Thursday, October 27, 9:30 p.m. BST | |
| Sydney, Friday, October 28, 7:30 a.m. AEDT |
Please note that ResMed does not use outside phone lines to access the earnings call.
A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from October 27 until November 10 at:
| • | U.S.: +1 877.660.6853 | |
| • | International: +1 201.612.7415 | |
| • | Conference ID: 13733726 |
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors Amy Wakeham +1 858.836.5000 investorrelations@resmed.com | For media Jayme Rubenstein +1 858.836.6798 news@resmed.com |
FAQ
When will ResMed release its Q1 FY 2023 financial results?
What time is the ResMed earnings call scheduled?
Where can I access the ResMed earnings webcast?
